PRLH

Across TCGA pan-cancer cohorts, PRLH mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRLH data layer compared with 23 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRLH mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRLH expression acts as an unfavorable survival marker.

PDAC and GBM are the cancer types where PRLH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.360	0.766	.035	6	view →
GBM	OS	Tertile	All	0.742	0.964	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRLH–PDAC (DFS)

Open the PDAC breakdown →